Treatments · Entity Annotation Prototype (beta)

3articles mentioning treatments

4treatment mentions

1distinct treatments extracted

0%of mentions human-reviewed

Active filtersEntity: lymphodepleting chemotherapy ×

lymphodepleting chemotherapy

This treatment is selected. Its supporting articles are shown below.

lymphodepleting chemotherapy3

Articles mentioning lymphodepleting chemotherapy

3 articles · page 1 of 1

592 Phase I study: CD39+CD103+CD8+ selected TIL therapy (AGX-148) demonstrates clinical activity in patients with metastatic solid tumors

jitc · abstract · 2025-11-04 · 2 matching annotations

84.1%

lymphodepleting chemotherapy AGX-148 oral head and neck squamous cell carcinoma melanoma thyroid cancer solid tumors Providence Institutional Review Board ClinicalTrials.gov

…ard and experimental therapies. Patients undergo tumor harvest, lymphodepleting chemotherapy, adoptive transfer of AGX-148 and high-dose IL-2 for one week, …

514 Biomarker insights and long-term outcomes of TILT-123 oncolytic adenovirus combined with tumor-infiltrating lymphocytes in refractory metastatic melanoma: results from the TUNINTIL phase 1 trial

jitc · abstract · 2025-11-04 · 1 matching annotations

77.6%

lymphodepleting chemotherapy TILT-123 MM Danish Medicines Agency FDA Danish National Ethics Committee igrelimogene litadenorepvec metastatic melanoma

…ation remains limited by significant toxicities associated with lymphodepleting chemotherapy and high-dose IL-2 regimens. Phase 1 trial TUNINTIL ( NCT042174…

578 A First-in-human phase I/IIa dose escalation trial evaluating the safety and preliminary efficacy of LEU011, a novel CAR-T, in subjects with relapsed/refractory solid tumors (AERIAL)

jitc · abstract · 2025-11-04 · 1 matching annotations

85.3%

lymphodepleting chemotherapy LDC LEU011 solid tumors solid tumours LEU01101 ClinicalTrials.gov North East - York Research Ethics Committee

… linear CAR. The trial hypothesis is that LEU011, combined with lymphodepleting chemotherapy (LDC), will be safe and tolerable, and will elicit efficacy in …